摘要
Abstract
Vitiligo is a prevalent dermatological condition characterized by depigmentation of the skin,its etiology and progression are influenced by a combination of genetic,oxidative stress,inflammatory,and environmental factors.Traditional treatments encompass a variety of options such as camouflage,topical corticosteroids,topical calcineurin inhibitors,oral corticosteroids,phototherapy,and surgical procedures,each with distinct limitations.In recent years,with the in-depth researchon the pathogenesis of vitiligo,Janus kinase(JAK)inhibitors have shown great potential in the treatment of vitiligo.Researches have demonstrated that JAK inhibitors can modulate immune response,facilitate melanocyte regeneration and migration through the inhibition of the JAK-ST AT signaling pathway,ultimately leading to the amelioration of skin lesions in individuals with vitiligo.Furthermore,numerous clinical trials have substantiated the effectiveness and safety of JAK inhibitors in the management of vitiligo.However,future studies and discussions are necessary on its long-term efficacy and potential side effects.Overall,JAK inhibitors provide new strategies and directions for the treatment of vitiligo.This article provided an overview of the research advancements in the use of JAK inhibitors for treating vitiligo,encompassing their mechanism of action,clinical utilization,and effectiveness assessment,and an reference for clinical practice.关键词
JAK抑制剂/生物制剂/白癜风/芦可替尼Key words
Janus inhibitors/Biological agent/Vitiligo/Ruxolitinib
